These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 1402213)

  • 41. Indobufen. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in cerebral, peripheral and coronary vascular disease.
    Wiseman LR; Fitton A; Buckley MM
    Drugs; 1992 Sep; 44(3):445-64. PubMed ID: 1382938
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Polytetrafluoroethylene use for above-knee femoropopliteal bypass in critical limb ischemia.
    El-Kayali AA
    Saudi Med J; 2003 Jun; 24(6):669-71. PubMed ID: 12847601
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prevention of early reocclusion by dipyridamole and ASA in arterial reconstructive surgery.
    Harajola PT; Meurala H; Frick MH
    J Cardiovasc Surg (Torino); 1981; 22(2):141-4. PubMed ID: 7014570
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antiplatelet drugs improve the patency rates after femoro-popliteal endarterectomy.
    Bollinger A; Brunner U
    Vasa; 1985; 14(3):272-9. PubMed ID: 4050068
    [No Abstract]   [Full Text] [Related]  

  • 45. Random control trial of a short course of aspirin and dipyridamole (Persantin) for femorodistal grafts.
    Clyne CA; Archer TJ; Atuhaire LK; Chant AD; Webster JH
    Br J Surg; 1987 Apr; 74(4):246-8. PubMed ID: 3555690
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Indobufen versus placebo in the prevention of restenosis after carotid endarterectomy: a double-blind pilot study.
    Pratesi C; Pulli R; Milanesi G; Lavezzari M; Pamparana F; Bertini D
    J Int Med Res; 1991; 19(3):202-9. PubMed ID: 1936509
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Drug-induced inhibition of platelet function delays progression of peripheral occlusive arterial disease. A prospective double-blind arteriographically controlled trial.
    Hess H; Mietaschk A; Deichsel G
    Lancet; 1985 Feb; 1(8426):415-9. PubMed ID: 2857803
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The effect of platelet inhibitory therapy on graft thromboresistance.
    Bearn PE; Bull H; Seddon AM; Marston A; McCollum CN
    Int J Exp Pathol; 1993 Oct; 74(5):425-31. PubMed ID: 8217777
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term evaluation of indobufen in peripheral vascular disease.
    Belcaro G; De Simone P
    Angiology; 1991 Jan; 42(1):8-14. PubMed ID: 1992862
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of dipyridamole (Persantin) on blood flow and patency of aortocoronary vein bypass grafts.
    Ekeström SA; Gunnes S; Brodin UB
    Scand J Thorac Cardiovasc Surg; 1990; 24(3):191-6. PubMed ID: 2293357
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of aspirin and dipyridamole on expanded polytetrafluoroethylene graft patency.
    Green RM; Roedersheimer LR; DeWeese JA
    Surgery; 1982 Dec; 92(6):1016-26. PubMed ID: 6755786
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The effect of indobufen on the thrombogenic potential of a Dacron prosthesis in an artificial circulation.
    Sheehan SJ; Monson JR; Salter MC; Rajah DS; Rajah SM; Kester RC
    Eur J Vasc Surg; 1988 Aug; 2(4):223-7. PubMed ID: 2975227
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of aspirin, dipyridamole, and cod liver oil on accelerated myointimal proliferation in canine veno-arterial allografts.
    DeCampli WM; Kosek JC; Mitchell RS; Handen CE; Miller DC
    Ann Surg; 1988 Dec; 208(6):746-54. PubMed ID: 3196097
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Indobufen in the prevention of thromboembolic complications in patients with heart disease. A randomized, placebo-controlled, double-blind study.
    Fornaro G; Rossi P; Mantica PG; Caccia ME; Aralda D; Lavezzari M; Pamparana F; Milanesi G
    Circulation; 1993 Jan; 87(1):162-4. PubMed ID: 8419003
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Inhibition of spontaneous platelet aggregation and adhesion by indobufen (K 3920). A randomized, double-blind crossover study on platelet, coagulation and fibrinolysis function tests.
    Nenci GG; Berrettini M; Iadevaia V; Parise P; Ballatori E
    Pharmatherapeutica; 1982; 3(3):188-94. PubMed ID: 7134226
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bleeding time and antiplatelet agents in normal volunteers.
    Pogliani EM; Fowst C; Bregani R; Corneo G
    Int J Clin Lab Res; 1992; 22(1):58-61. PubMed ID: 1633323
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Aspirin and arteriovenous graft thrombosis in hemodialysis: just what the doctor ordered?
    Bech FR; Chertow GM
    J Am Soc Nephrol; 2011 Apr; 22(4):595-7. PubMed ID: 21415154
    [No Abstract]   [Full Text] [Related]  

  • 58. Lipid peroxidation products and changes in phospholipid composition induced by indobufen in diabetic platelets.
    Dmoszyńska A; Walter-Croneck A; Ledwozyw A
    Thromb Res; 1995 Sep; 79(5-6):483-90. PubMed ID: 7502274
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Femoropopliteal vein bypass: the problem proximal anastomosis.
    Samson ID
    Arch Surg; 1978 Jun; 113(6):779. PubMed ID: 350194
    [No Abstract]   [Full Text] [Related]  

  • 60. Long-term antiplatelet activity and safety of indobufen in patients with cardiovascular disease. Italian Multicenter Study Group.
    Int J Clin Pharmacol Ther Toxicol; 1985 Aug; 23(8):439-46. PubMed ID: 3899952
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.